Cancer Drugmaker Apollomics Agrees to Merge with Maxpro SPAC
Apollomics is working on nine types of drugs for difficult-to-treat forms of lung cancer and leukemia.
Stay updated with breaking news from Maxpro Ventures Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apollomics is working on nine types of drugs for difficult-to-treat forms of lung cancer and leukemia.
14.10.2021 - Taipei City, Oct. 13, 2021 (GLOBE NEWSWIRE) - via NewMediaWire - Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, today announced the closing of its initial public offering (the “Offering”) of 9,000,000 units at $10.00 per ...
Taipei City, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, today announced...
08.10.2021 - Taipei City, Oct. 07, 2021 (GLOBE NEWSWIRE) - via NewMediaWire - Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, announced today that it priced its initial public offering of $90 million, consisting of 9,000,000 units at ...
Taipei City, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, announced today...